Trafalgar International (GCAN) Restructuring Costs (2017)
Greater Cannabis Company (GCAN) posted quarterly Restructuring Costs of $9315.0 for Q3 2017.
Trafalgar International (GCAN) Restructuring Costs (2017) Analysis & Trends
Greater Cannabis Company's Restructuring Costs history runs 1 years deep, the most recent figure standing at $9315.0 for Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 9,315.00 |